Nobuko Kato
Chief Communications & Investor Relations Officer

[Interpreted]

Thank you very much for your attendance in this fiscal 2025 earnings call by Astellas Inc. I am Kato, Chief Communications and IR Officer. I would like to serve as a moderator for today. Following our presentation today, we will move on to the Q&A session. The presentation will be based on the presentation materials available on our website. Simultaneous interpretation in Japanese and English will be provided throughout the event, including the Q&A session.

Please note that we cannot guarantee the accuracy of it. [Operator Instructions] This material or our presentation and answers and statement in the Q&A session includes forward-looking statements based on assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties.

Actual financial results may differ materially depending on a number of factors. They contain information on pharmaceuticals, including compounds under development, but this information is not intended to make any advertisements nor provide medical advice of any kind.

Now let me introduce you the participants from Astellas. Here today. Naoki Okamura, President, CEO; Clinical Research and Development Officer, Tadaaki Taniguchi; Chief